Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company provides pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Abbott Laboratories

Earnings reports, mergers, and other data are among the top stock market stories on Thursday.


Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!

Shares of Exact Sciences ($EXAS), the cancer screening and treatment provider, surged by about 18% on Thursday morning after it agreed to merge wit...

M&A News: Exact Sciences Stock (EXAS) Jumps 18% on Abbott’s $21B Acquisition

American Bitcoin Corp. ( ($ABTC) ) has released its Q3 earnings. Here is a breakdown of the information American Bitcoin Corp. presented to its inv...

American Bitcoin Corp. Reports Strong Q3 2025 Growth

In a report released on October 27, Mattia Petracca from Integrae SIM maintained a Buy rating on ALFIO BARDOLLA Training Group S.P.A., with a price...

Integrae SIM Keeps Their Buy Rating on ALFIO BARDOLLA Training Group S.P.A. (ABTG)

Abbott Laboratories (($ABT)) announced an update on their ongoing clinical study. Abbott Laboratories is conducting a study titled ‘Study of the Ef...

Abbott’s New Study on Dydrogesterone: A Potential Game-Changer for Endometriosis Pain

TD Cowen analyst Josh Jennings reiterated a Buy rating on Abbott Laboratories today and set a price target of $145.00. The company’s shares opened ...

TD Cowen Reaffirms Their Buy Rating on Abbott Laboratories (ABT)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Abbott Laboratories (ABT – Research Report), Roche Holding AG (RH...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ABT	$128.11	+3.34%	9.40M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ABT	$128.11	+3.3%	9.40M
3
4
5
6

ABT

ABT

No Data Available

Get Abbott Laboratories Data in Excel

Get Abbott Laboratories Data in Excel